---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-036335"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-11-27T23:59:59+00:00"
generated_at: "2026-05-29T13:26:22.382912+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CervoMed's neflamapimod gets FDA Orphan Drug Designation for frontotemporal dementia

## Summary
- FDA granted Orphan Drug Designation for neflamapimod to treat frontotemporal dementia (FTD).
- Designation recognizes scientific rationale; FTD currently has no approved treatment options.
- CervoMed in discussions with clinical thought leaders to design a proof-of-principle FTD study.
- Company on track to report topline data from RewinD-LB Phase 2b trial in DLB in December 2024.
- Benefits include development assistance, tax credits, fee exemptions, and 7-year post-approval exclusivity.

## SEC filing metadata
- accession: 0001437749-24-036335
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-11-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924036335/0001437749-24-036335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924036335/crvo20241127_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-036335
- JSON: https://secwatch.observer/filing/0001437749-24-036335.json
- Plain text: https://secwatch.observer/filing/0001437749-24-036335.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.